New pill could ease deadly lung pressure condition
NCT ID NCT07441278
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an oral drug called NS-863 in 177 adults with pulmonary hypertension linked to interstitial lung disease (PH-ILD). Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goal is to see if the drug improves blood vessel resistance in the lungs and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NS-863 (an oral drug)
- What this could lead to
- If successful, this could point toward a new oral treatment to improve blood flow in the lungs for people with PH-ILD.
- What could go wrong
- This is an early Phase 2 trial with only 177 participants, so results may not confirm benefit. The drug could also cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.